Valneva SE (VALN)
4.31
0.04 (0.94%)
At close: Jan 15, 2025, 3:44 PM
4.31
0.00%
After-hours Jan 15, 2025, 03:45 PM EST
undefined% (undefined)
| Bid | 3.51 |
| Market Cap | 349.98M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.12 |
| PE Ratio (ttm) | -35.92 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 6.4 |
| Volume | 40,453 |
| Avg. Volume (20D) | 40,844 |
| Open | 4.30 |
| Previous Close | 4.27 |
| Day's Range | 4.27 - 4.45 |
| 52-Week Range | 3.62 - 9.50 |
| Beta | undefined |
About VALN
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile tox...
Industry Biotechnology
Sector Healthcare
IPO Date May 5, 2021
Employees 676
Stock Exchange NASDAQ
Ticker Symbol VALN
Website https://valneva.com
Analyst Forecast
According to 2 analyst ratings, the average rating for VALN stock is "Buy." The 12-month stock price forecast is $18.5, which is an increase of 329.22% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Valneva SE is scheduled to release its earnings on Mar 20, 2025,
before market opens.
Analysts project revenue of $66.10M, reflecting a 46.56% YoY growth and earnings per share of -0.24, making a -52.00% decrease YoY.
Analysts project revenue of $66.10M, reflecting a 46.56% YoY growth and earnings per share of -0.24, making a -52.00% decrease YoY.
5 months ago ·
Source
+7.35%
Valneva shares are trading higher. The company rep...
Unlock content with
Pro Subscription
6 months ago ·
Source
+1.43%
Valneva shares are trading higher after the company received marketing authorization in Europe for its Chikungunya vaccine, IXCHIQ.
